

FORM 51-102F3

Material Change Report

Item 1. Name and Address of Company

Blackhawk Growth Corp. (the “Company”)
Suite 2200, 885 West Georgia Street
Vancouver, B.C., V6C 3E8

Item 2. Date of Material Change

News Release dated Mar 15, 2022

Item 3. News Release

The Company disseminated a news release concerning the material change described herein on March 15, 2022 and subsequently filed a copy on SEDAR at www.sedar.com.

Item 4. Summary of Material Change

Blackhawk’s MindBio Therapeutics announces acquisition pathway to accelerate clinical trials and drug development activities.

Item 5. Full Description of Material Change

Vancouver, British Columbia – March 15, 2022 – Blackhawk Growth Corp. (CSE:BLR; Frankfurt:OJJ) (the “**Company**” or “**Blackhawk**”) is pleased to report that MindBio Therapeutics (“MindBio”) has co-invested in *Quantified Citizen’s* (quantifiedcitizen.com) latest funding round with other notable investors around the world. The investment was funded from MindBio existing working capital.

Quantified Citizen is a leading mobile health research platform with over 52,000 users and over 17,000 participants in their global microdosing study, which was published in the prestigious science journal [Nature Scientific Reports](#).

MindBio is in the final completion stages of a world first Phase 1 clinical trial microdosing LSD to patients at home. The investment in Quantified Citizen will allow MindBio to further its footprint in Microdosing of psychedelics.

Quantified Citizen has created an innovative health technology platform that seeks to democratize scientific discovery through digitized health measures and a community of professional researchers and passionate citizen scientists. “We envision a world where doing scientifically valid health research is as fast and easy as creating a website, with the same global reach. Where scientific tinkering and self-examination are normalized, vastly accelerating the pace of discovery by unlocking unexamined data,” shares co-founder and CEO Eesmyal Santos-Brault.

MindBio is actively seeking new acquisition opportunities to expand its global reach of clinical trials and drug development activities. Management is regularly reviewing new opportunities that may add value to both MindBio and Blackhawk's Digital Mind Technologies.

Justin Hanka, Founder of MindBio says "since MindBio is on path to spin out of Blackhawk and list on the CSE, now is an opportune time to cast our net and find acquisitions that can accelerate our path to commercializing new treatments for mental health conditions."

About Blackhawk Growth

Blackhawk is an investment holding company looking to create substantial value for its shareholders through the acquisition and development of high growth companies. It has focused its investments in the health, cannabis and cannabidiol industries in both Canada and the United States. Its portfolio of companies includes Sac Pharma, LeichtMind Clinics, Noble Hemp, Spaced Food, Stable Foods Co., MindBio Therapeutics, Digital Mind Technologies as well as an equity position in Gaia Grow Corp. (CSE:GAIA).

The Company diligently posts updates through videos from the official company YouTube channel <https://www.youtube.com/channel/UCs4f2tt3yAvOGhNLjgNOy-A>

Please join the conversation on our Blackhawk group supporter's telegram group at <https://t.me/Blackhawkgrowthcorp> and visit us online at <https://www.blackhawkgrowth.com>.

For further information please contact:

Frederick Pels, Chief Executive Officer

(403)-991-7737

fred@blackhawkgrowth.com

Item 6. Reliance on subsection 7.1(2) or (3) of National Instrument 51-102

Not applicable

Item 7. Omitted Information

Not applicable

Item 8. Executive Officer

The following senior officer of the Company is knowledgeable about the material change disclosed in this report.

Frederick Pels
Chief Executive Officer

Telephone: 403-991-7737

Item 9.

Date of Report

March 15, 2022